SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Who May Qualify: - Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1 prior line of systemic therapy for advanced disease - Adult 18 years of age or older. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. - Has at least 1 measurable lesion by iRECIST for ovarian cancer or cholangiocarcinoma or lesions measurable for mRECIST for mesothelioma. - Satisfactory Blood coagulation parameters - Satisfactory organ and bone marrow function Who Should NOT Join This Trial: - Active invasive cancers other than mesothelioma, cholangiocarcinoma, and ovarian unless surgically and medically cured without evidence of recurrent disease for 5 years. - History of T or B cell malignancies or previous gene-engineered T cell therapies. - Sarcomatoid/biphasic mesothelioma. - Pulmonary exclusions - Have acquired hereditary, congenital weakened immune system or have recognized weakened immune system disease - Active hepatitis B, active hepatitis C, or any HIV infection at the time of screening - Active autoimmune conditions (where your immune system attacks your own body) Always talk to your doctor about whether this trial is right for you.